Qulipta denied by insurance? Appeal and win.
A denial of Qulipta is rarely the final word. It is the opening of a process, and these denials are frequently overturned when the appeal is built correctly. Qulipta is most often denied because the plan requires step therapy through older oral preventives first, or because the prior authorization criteria were not fully documented in the original submission. What flips the decision is a clear record of your migraine diagnosis, the preventives you have already tried and failed or could not tolerate, and a letter of medical necessity that maps your history directly to the plan's own coverage rules.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Qulipta is FDA approved for the preventive treatment of migraine in adults. This covers both episodic migraine, meaning fewer than 15 headache days per month, and chronic migraine, meaning 15 or more headache days per month. It is taken once daily as an oral tablet and is intended to reduce how often migraine attacks occur, not to relieve an attack already in progress. It is not approved to treat acute migraine and is not approved for use in children.
Why Qulipta gets denied
- Step therapy not satisfied: the plan requires a documented trial and failure or intolerance of one or more older oral preventives (such as topiramate, a beta-blocker, or amitriptyline) before it will cover a gepant.
- Prior authorization criteria not fully documented: the submission lacked the migraine diagnosis, monthly migraine day count, or evidence of prior preventive trials that the plan's PA form requires.
- Non-formulary or unfavorable tier: many plans place Qulipta on a high tier or off formulary and prefer a CGRP injectable or a different gepant, triggering a formulary or tier exception requirement.
- Concurrent CGRP therapy: the plan will deny Qulipta if the patient is already on another CGRP agent (such as an injectable monoclonal antibody like erenumab or a second gepant), since combined CGRP-pathway use is not supported by approval data.
What a winning appeal includes
- Documented migraine diagnosis with the correct ICD-10 code (for example G43.709 for chronic migraine without status migrainosus, or G43.009 for migraine without aura), plus a headache diary showing monthly migraine days.
- A clear record of prior preventives tried, including drug names, dates, duration, and the specific reason each failed or was stopped (lack of efficacy, side effects, or contraindication), which satisfies or supports an exception to step therapy.
- A letter of medical necessity that maps the patient's history line by line to the plan's own published PA criteria and cites the FDA-approved preventive indication for episodic or chronic migraine.
- Documentation specific to Qulipta, such as the once-daily oral dosing, the absence of any contraindication, no concurrent CGRP therapy, and review of CYP3A4 interactions, showing the prescription is clinically appropriate and correctly dosed.
How we approach the appeal
Choose the path that matches the stated denial reason. If the drug is non-formulary or on a high tier, file a formulary or tier exception arguing the preferred alternatives are inappropriate or have failed. If the denial is a step therapy or PA criteria issue, file a prior authorization appeal or step therapy exception and quote the plan's own language, which typically requires a "diagnosis of migraine" and a "trial and failure of one or more preventive medications." Attach the headache diary, the prior-therapy record, and the letter of medical necessity so the reviewer can check each criterion off against your documentation rather than guessing.
Qulipta appeal letter template
Copy this Qulipta appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Oral CGRP receptor antagonist (gepant) denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Qulipta denial I am appealing the denial of Qulipta (atogepant). I request that the denial be overturned and Qulipta approved. 1. The denial. [Insurer] denied Qulipta stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Qulipta is medically necessary for my condition. Choose the path that matches the stated denial reason. If the drug is non-formulary or on a high tier, file a formulary or tier exception arguing the preferred alternatives are inappropriate or have failed. If the denial is a step therapy or PA criteria issue, file a prior authorization appeal or step therapy exception and quote the plan's own language, which typically requires a "diagnosis of migraine" and a "trial and failure of one or more preventive medications." Attach the headache diary, the prior-therapy record, and the letter of medical necessity so the reviewer can check each criterion off against your documentation rather than guessing. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Qulipta within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Qulipta denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan denied Qulipta and said I have to try another migraine preventive first. Do I have to start over?
Not necessarily. This is a step therapy denial, and you can request a step therapy exception. If you have already tried older preventives such as topiramate, a beta-blocker, or amitriptyline and they failed or caused side effects, document the drug names, dates, and reasons each was stopped. A prior trial that was not captured in the original submission often satisfies the requirement once it is properly recorded, so you may not need to repeat anything.
My insurance covers the CGRP injections but denied the Qulipta pill. Can I appeal?
Yes. Plans sometimes prefer an injectable CGRP and place the oral gepant on a higher tier or off formulary. You can file a formulary or tier exception explaining why the oral option is medically appropriate for you, for example a preference or clinical need to avoid injections, prior failure of an injectable, or a tolerability issue. The appeal should map your situation to the plan's exception criteria and include a letter of medical necessity from your prescriber.
Will my plan cover Qulipta if I am already using another migraine prevention medication?
It depends on the medication. Qulipta can generally be combined with non-CGRP preventives, but plans will deny it if you are already taking another drug that works on the CGRP pathway, such as an injectable CGRP antibody or a second gepant, because using two CGRP agents together is not supported by approval data. If that is the reason for denial, the appeal usually involves your prescriber confirming the plan to stop or switch from the other CGRP agent so only one is in use.
Qulipta denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.